HK1213480A1 - 用於持續釋放蛋白質的生物可降解的藥物遞送系統 - Google Patents

用於持續釋放蛋白質的生物可降解的藥物遞送系統

Info

Publication number
HK1213480A1
HK1213480A1 HK16101450.3A HK16101450A HK1213480A1 HK 1213480 A1 HK1213480 A1 HK 1213480A1 HK 16101450 A HK16101450 A HK 16101450A HK 1213480 A1 HK1213480 A1 HK 1213480A1
Authority
HK
Hong Kong
Prior art keywords
proteins
drug delivery
sustained release
delivery systems
biodegradable drug
Prior art date
Application number
HK16101450.3A
Other languages
English (en)
Inventor
Cindy W Wu
Michael R Robinson
James A Burke
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1213480A1 publication Critical patent/HK1213480A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HK16101450.3A 2012-09-27 2016-02-05 用於持續釋放蛋白質的生物可降解的藥物遞送系統 HK1213480A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706516P 2012-09-27 2012-09-27
PCT/US2013/061803 WO2014052518A1 (en) 2012-09-27 2013-09-26 Biodegradable drug delivery systems for the sustained release of proteins

Publications (1)

Publication Number Publication Date
HK1213480A1 true HK1213480A1 (zh) 2016-07-08

Family

ID=49447799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101450.3A HK1213480A1 (zh) 2012-09-27 2016-02-05 用於持續釋放蛋白質的生物可降解的藥物遞送系統

Country Status (13)

Country Link
US (2) US10653621B2 (zh)
EP (1) EP2900250B1 (zh)
JP (1) JP6317748B2 (zh)
KR (2) KR20200065106A (zh)
CN (1) CN104812397A (zh)
AU (2) AU2013323553B2 (zh)
BR (1) BR112015006929A2 (zh)
CA (1) CA2886081A1 (zh)
ES (1) ES2709351T3 (zh)
HK (1) HK1213480A1 (zh)
RU (1) RU2676102C2 (zh)
TW (1) TWI663985B (zh)
WO (1) WO2014052518A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192590A2 (en) * 2016-05-02 2017-11-09 The Regents Of The University Of Michigan Coated implants for long-term controlled release of antibody therapeutics
IL271908B2 (en) * 2017-07-11 2024-02-01 Sustained Nano Systems Llc Over-compressed pharmaceutical preparations
KR20200130392A (ko) * 2018-03-09 2020-11-18 발리터 인코포레이티드 관절 염증의 지속적인 관절내 치료를 위한 다가 펩티드 컨쥬게이트
EP3801378A4 (en) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
AU2019413436A1 (en) * 2018-12-28 2021-07-01 National Cheng Kung University Biological scaffold and method for fabricating the same
CN110051650A (zh) * 2019-04-29 2019-07-26 南京锐利施生物技术有限公司 用于玻璃体注射的贝伐单抗和***共载的纳米粒药物
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
GB202018889D0 (en) * 2020-12-01 2021-01-13 UCB Biopharma SRL Formulations
CN117203178A (zh) * 2021-02-24 2023-12-08 治疗调适公司 陶瓷组合物和使用方法
GB202103785D0 (en) * 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL155479A0 (en) 2000-11-03 2003-11-23 Control Delivery Sys Inc Improved device and method for treating conditions of a joint
CA2460587A1 (en) 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PT1660057E (pt) 2003-08-27 2012-08-02 Ophthotech Corp Terapia de associação para o tratamento de distúrbios neovasculares oculares
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
JP4595408B2 (ja) 2004-07-08 2010-12-08 パナソニック株式会社 圧縮機
US20060020044A1 (en) 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for treating or preventing macular-degeneration related disorders
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070178138A1 (en) 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090258924A1 (en) 2008-04-15 2009-10-15 Allergan, Inc. METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP2012515603A (ja) * 2009-01-27 2012-07-12 サイレンシード リミテッド インプラント送達の方法とシステム
WO2011041642A1 (en) * 2009-10-01 2011-04-07 Surmodics Pharmaceuticals, Inc. Microparticle compositions and methods for treating age-related macular degeneration
AU2011292149A1 (en) 2010-08-17 2013-03-14 Allergan, Inc. Method of stabilizing and sterilizing peptides or proteins

Also Published As

Publication number Publication date
CN104812397A (zh) 2015-07-29
EP2900250A1 (en) 2015-08-05
TW201417831A (zh) 2014-05-16
ES2709351T3 (es) 2019-04-16
AU2018247260A1 (en) 2018-11-01
KR20200065106A (ko) 2020-06-08
RU2015115358A (ru) 2016-11-20
JP6317748B2 (ja) 2018-04-25
US20140086974A1 (en) 2014-03-27
KR20150058510A (ko) 2015-05-28
BR112015006929A2 (pt) 2017-07-04
US10653621B2 (en) 2020-05-19
RU2676102C2 (ru) 2018-12-26
JP2015532284A (ja) 2015-11-09
US20200261358A1 (en) 2020-08-20
TWI663985B (zh) 2019-07-01
WO2014052518A1 (en) 2014-04-03
AU2013323553B2 (en) 2018-07-12
AU2018247260B2 (en) 2020-09-17
EP2900250B1 (en) 2018-11-07
CA2886081A1 (en) 2014-04-03
AU2013323553A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
HK1213480A1 (zh) 用於持續釋放蛋白質的生物可降解的藥物遞送系統
HK1208374A1 (zh) 用於疏水組合物的生物可降解藥物遞送
HK1205928A1 (zh) 種眼部給藥系統
HK1206634A1 (zh) 用於控制釋放不同藥物成分的媒介物
BR112013018828A2 (pt) sistemas de distribuição de droga
IL245544A0 (en) drug delivery system
ZA201502352B (en) Liposomal drug delivery system
HK1205010A1 (zh) 用於遞送藥物的系統
PL2654864T3 (pl) System dostarczania leku
SG10201701773UA (en) Hyaluronic Acid-Based Drug Delivery Systems
HK1202418A1 (zh) 用於生物活性試劑的緩釋的藥物遞送系統
EP2630971B8 (en) Combinations of albumin-based drug delivery systems
EP2849770A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS
ZA201207900B (en) Fast dissolving drug delivery systems
EP2818140A4 (en) STENT DELIVERY SYSTEM
EP2968162A4 (en) Multi-stage biodegradable drug delivery platform
EP2682075A4 (en) STENT PLACEMENT SYSTEM
EP2921152A4 (en) DRUG DELIVERY SYSTEM
HK1204258A1 (zh) 配藥系統
EP2689753A4 (en) STENT DELIVERY SYSTEM
ZA201309156B (en) Drug delivery system
IL227352A0 (en) A system for ocular administration of a drug
EP2679202A4 (en) STENT PLACEMENT SYSTEM
IL236757B (en) A device for administering a drug with retention in the digestive tract
EP2717802A4 (en) RECOVERABLE STENT DISPENSING SYSTEM